Potency of clinical group B streptococcal conjugate vaccines.
暂无分享,去创建一个
[1] D. Kasper,et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. , 2000, The Journal of infectious diseases.
[2] D. Kasper,et al. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate. , 2000, The Journal of infectious diseases.
[3] A. Schuchat,et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. , 2000, The New England journal of medicine.
[4] D. Kasper,et al. Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII. , 1999, The Journal of infectious diseases.
[5] D. Kasper,et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. , 1999, The Journal of infectious diseases.
[6] D. Kasper,et al. Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice. , 1997, The Journal of infectious diseases.
[7] D. Kasper,et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1996, The Journal of clinical investigation.
[8] D. Kasper,et al. Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons , 1996, Infection and immunity.
[9] D. Kasper,et al. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1995, The Journal of infectious diseases.
[10] D. Kasper,et al. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. , 1994, The Journal of clinical investigation.
[11] D. Kasper,et al. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine , 1993, Infection and immunity.
[12] D. Kasper,et al. Neonatal mouse model of group B streptococcal infection. , 1992, The Journal of infectious diseases.
[13] D. Kasper,et al. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. , 1990, The Journal of clinical investigation.
[14] J. Shiloach,et al. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid , 1990, Infection and immunity.
[15] L. Reed,et al. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .